The course of COVID-19 in patients with hematological malignancies and risk factors affecting mortality: A cross-sectional study
Hematol., Transfus. Cell Ther. (Impr.)
; 46(1): 3-7, Jan.-Mar. 2024. tab
Article
in En
| LILACS
| ID: biblio-1557888
Responsible library:
BR408.1
Localization: BR408.1
ABSTRACT
Objective This study aimed to determine the clinical outcomes and risk factors affecting mortality in patients with COVID-19 following hematological malignancy (HM). Methods Patients diagnosed with HM and hospitalized for COVID-19 were included in this retrospective study. The age, demographic and clinical characteristics, prognosis and treatment of surviving and non-surviving patients were compared. Results A total of 49 patients were included in this study, 17 (34.6%) of whom died within 28 days of being diagnosed with COVID-19. Older age (p = 0.001), diabetes (p = 0.001), chronic obstructive pulmonary disease (p = 0.002), secondary infection (p < 0.001) and secondary bacterial infection (p = 0.005) were statistically significantly higher in non-survivors. The remission status of HM was higher in surviving patients (p < 0.001). In multivariate regression analysis, age (OR 1.102, p = 0.035) and secondary infection (OR 16.677, p = 0.024) were risk factors increasing mortality, the remission status of HM (OR 0.093, p = 0.047) was a protective factor from mortality. Conclusion The older age, the remission status of HM and secondary infection due to COVID-19 were determined as prognostic factors predicting mortality in HM patients with following COVID-19.
Key words
Full text:
1
Collection:
01-internacional
Database:
LILACS
Main subject:
Hematologic Neoplasms
Language:
En
Journal:
Hematol., Transfus. Cell Ther. (Impr.)
Journal subject:
Hematologia
/
TransfusÆo de Sangue
Year:
2024
Document type:
Article
Affiliation country:
Turquía
Country of publication:
Brasil